Patent details

EP1856135 Title: Prodrugs of 2,4-pyrimidinediamine compounds and their uses.

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
EP1856135
WO Application Number:
Type:
European Patent Granted for NL
Status:
Patent in Force
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP06718943.1
WO Publication Number:
EPO Publication Language:
English
SPC Number:
301039
First Applicant Residence Country:
United States of America (US)
Publications:

Dates

Filing date:
19/01/2006
Grant date:
09/12/2009
EP Publication Date:
09/12/2009
WO Publication Date:
Claims Translations Received Date:
Claims Translation B1 Received Date:
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
09/12/2009
EP B1 Publication Date:
09/12/2009
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
22/02/2010
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
18/01/2026
Lapsed By Expiration Date:
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
09/12/2009
 
 

 

Name:
Rigel Pharmaceuticals, Inc.
Address:
1180 Veterans Blvd., 94080, South San Francisco, California, United States of America (US)

Domicile Holder

Name:
ir. F.A. Geurts c.s.
From:
09/12/2009
Address:
Octrooibureau Vriesendorp & Gaade B.V. Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:

Inventor

1

Name:
Rajinder SINGH
Address:
94002, Belmont, California, United States of America (US)

2

Name:
Somasekhar BHAMIDIPATI
Address:
94404, Foster City, California, United States of America (US)

3

Name:
Esteban MASUDA
Address:
94025, Menlo Park, California, United States of America (US)

4

Name:
Valentino J. STELLA
Address:
KS 66044, Lawrence, United States of America (US)

5

Name:
Thomas SUN
Address:
CA 94555, Fremont, United States of America (US)

Licensee

Name:
AstraZeneca AB
From:
12/04/2012
Address:
Västra Mälarehamnen 9, SE-151-85, Södertälje, Sweden (SE)
To:

Priority

1

Priority Patent Number:
654620 P
Priority Date:
18/02/2005
Priority Country:
United States of America (US)

2

Priority Patent Number:
645424 P
Priority Date:
19/01/2005
Priority Country:
United States of America (US)

Classification

Main IPC Class:
C07F 9/6561;
IPC or IDT classification:
A61K 31/5383; A61K 31/675; A61P 37/00; C07D 498/04;

Publication

Bulletin

1

Bulletin Heading:
MED
Journal edition number:
2013/50
Publication date:
11/12/2013
Description:
Other communications

2

Bulletin Heading:
MED
Journal edition number:
2013/05
Publication date:
30/01/2013
Description:
Other communications

3

Bulletin Heading:
EP3
Journal edition number:
2010/06
Publication date:
24/03/2010
Description:
European patents granted for the Netherlands in which a translation was filed ex Article 52 par. 1 of the NL Patent Law 1995

4

Bulletin Heading:
EP2
Journal edition number:
2010/02
Publication date:
01/02/2010
Description:
European patents granted for the Netherlands

European Patent Bulletin

Issue number:
200950
Publication date:
09/12/2009
Description:
Grant (B1)

Deed

Licence

Change Kind/ Decision Type:
Licence termination
Deed Number:
020996-A020996-1
Date Registered:
26/11/2013
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. M.F.J.M. Ketelaars c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Licence

Change Kind/ Decision Type:
New licence registration
Deed Number:
LRFC-502A
Date Registered:
04/01/2013
License Effective Date:
12/04/2012
License Expiration Date:
26/11/2013
Scope of License:
Not Exclusive
Journal Edition Number:
Text:
Beeindiging Licentie door NLO. Zie verder de akte. Expired
Deed Status:
Country Code:
Netherlands (NL)
Updated License Number:
Terminated License Number:

Added Licensee(s)

Name:
AstraZeneca AB
Address:
Västra Mälarehamnen 9, SE-151-85, Södertälje, Sweden (SE)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Licence

Change Kind/ Decision Type:
New licence registration
Deed Number:
019020-A019020-1
Date Registered:
04/01/2013
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. M.F.J.M. Ketelaars c.s.
Journal Edition Number:
Text:
Exclusieve licentie ingediend op 4 januari 2013 door Nederlands Octrooibureau te Den Haag. Licentiegever is Rigel Pharmaceuticals, Inc te San Fransisco, Verenigd Staten van Amerika. Zie verder akte.
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
27/01/2025
Last Annual Fee Paid Number:
20
Last Annual Fee Paid Amount:
1400 Euro
Payer:
Computer Packages Inc. (CPI)
Filing date Document type Document Description Number of pages File Type
22/02/2010 Claims Translated claims 2 PDF /3/4/9/8/1/0506718943/docs/ep06718943.1_0_claims20100222.pdf
22/02/2010 Incoming Correspondence Paper Other 1 PDF /3/4/9/8/1/0506718943/docs/ep06718943.1_3_incomingcorrespondencepaper20100222.pdf
16/12/2009 Incoming Correspondence Paper Other 1 PDF /3/4/9/8/1/0506718943/docs/ep06718943.1_2_incomingcorrespondencepaper20091216.pdf
07/12/2009 Incoming Correspondence Paper Other 1 PDF /3/4/9/8/1/0506718943/docs/ep06718943.1_1_incomingcorrespondencepaper20091207.pdf